The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

Parenteral fish oil, an adjuvant pharmacotherapy for COVID-19?

Parenteral fish oil, an adjuvant pharmacotherapy for COVID-19?
Parenteral fish oil, an adjuvant pharmacotherapy for COVID-19?
The new coronavirus 2 associated to severe acute respiratory syndrome (SARS-CoV-2), surprisingly, does not affect only the lung. The severe response to SARS-CoV-2 appears to include a “cytokine storm”, which indicates a state of hyperinflammation and subsequent dysfunction of multiple organs and tissues in the most severe cases. This could be the reason why populations at highest risk of death from the SARS-CoV-2 infection-induced disease (COVID-19) are those suffering from chronic low-grade inflammation, but prone to hyperinflammation - advanced age, obesity, type 2 diabetes, hypertension and metabolic syndrome. Inflammation resolution is strongly dependent on lipid mediators, the specialized pro-resolution mediators (SPMs). Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are precursors of very potent SPMs, including resolvins, protectins and maresins. In addition, they are associated with a less aggressive inflammatory initiation, after competing with omega-6 fatty acids for eicosanoid synthesis. Therefore, it makes sense to consider the use of n-3 PUFAs for clinical management of COVID-19 patients. N-3 PUFAs may be given by oral, enteral or parenteral routes, but the parenteral route favors their faster incorporation into plasma phospholipids, blood cells and tissues. Here, we discuss these aspects to propose the parenteral infusion of n-3 PUFAs as an adjuvant immunepharmacotherapy for hospitalized patients with COVID-19.
0899-9007
1-15
Torrinhas, Raquel S.
bfa6e685-ef9a-429d-b737-27d9a152a215
Calder, Philip
1797e54f-378e-4dcb-80a4-3e30018f07a6
Lemos, Gabriela O.
f8b74a5f-6ff8-43d2-b26a-b97a244b6541
Waitzberg, Dan L.
87eb74ac-e41e-4c03-bb8a-1937e1dc9d74
Torrinhas, Raquel S.
bfa6e685-ef9a-429d-b737-27d9a152a215
Calder, Philip
1797e54f-378e-4dcb-80a4-3e30018f07a6
Lemos, Gabriela O.
f8b74a5f-6ff8-43d2-b26a-b97a244b6541
Waitzberg, Dan L.
87eb74ac-e41e-4c03-bb8a-1937e1dc9d74

Torrinhas, Raquel S., Calder, Philip, Lemos, Gabriela O. and Waitzberg, Dan L. (2021) Parenteral fish oil, an adjuvant pharmacotherapy for COVID-19? Nutrition, 81, 1-15, [110900]. (doi:10.1016/j.nut.2020.110900).

Record type: Article

Abstract

The new coronavirus 2 associated to severe acute respiratory syndrome (SARS-CoV-2), surprisingly, does not affect only the lung. The severe response to SARS-CoV-2 appears to include a “cytokine storm”, which indicates a state of hyperinflammation and subsequent dysfunction of multiple organs and tissues in the most severe cases. This could be the reason why populations at highest risk of death from the SARS-CoV-2 infection-induced disease (COVID-19) are those suffering from chronic low-grade inflammation, but prone to hyperinflammation - advanced age, obesity, type 2 diabetes, hypertension and metabolic syndrome. Inflammation resolution is strongly dependent on lipid mediators, the specialized pro-resolution mediators (SPMs). Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are precursors of very potent SPMs, including resolvins, protectins and maresins. In addition, they are associated with a less aggressive inflammatory initiation, after competing with omega-6 fatty acids for eicosanoid synthesis. Therefore, it makes sense to consider the use of n-3 PUFAs for clinical management of COVID-19 patients. N-3 PUFAs may be given by oral, enteral or parenteral routes, but the parenteral route favors their faster incorporation into plasma phospholipids, blood cells and tissues. Here, we discuss these aspects to propose the parenteral infusion of n-3 PUFAs as an adjuvant immunepharmacotherapy for hospitalized patients with COVID-19.

Text
Parenteral fish oil in COVID-19 - Manuscript - Accepted Manuscript
Download (133kB)

More information

Accepted/In Press date: 13 May 2020
e-pub ahead of print date: 20 June 2020
Published date: January 2021

Identifiers

Local EPrints ID: 440710
URI: http://eprints.soton.ac.uk/id/eprint/440710
ISSN: 0899-9007
PURE UUID: 6390c571-4fcb-4f62-983b-18d4eee92e50
ORCID for Philip Calder: ORCID iD orcid.org/0000-0002-6038-710X

Catalogue record

Date deposited: 14 May 2020 16:30
Last modified: 13 May 2021 04:01

Export record

Altmetrics

Contributors

Author: Raquel S. Torrinhas
Author: Philip Calder ORCID iD
Author: Gabriela O. Lemos
Author: Dan L. Waitzberg

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×